Expand AKBA Menu
AKBA MENU

AKBA Latest Press Releases

-- January 13, 2025 --

Akebia Therapeutics Announces Multiple Positive Business Updates PRNewswire 8:00 AM

-- January 2, 2025 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM

-- December 18, 2024 --

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference PRNewswire 8:00 AM

-- December 3, 2024 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo (vadadustat) for CKD Patients on Dialysis PRNewswire 7:00 AM

-- November 25, 2024 --

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference PRNewswire 8:00 AM

-- November 14, 2024 --

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease PRNewswire 8:00 AM

-- November 12, 2024 --

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference PRNewswire 8:00 AM

-- November 7, 2024 --

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PRNewswire 7:00 AM

-- November 1, 2024 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights PRNewswire 8:00 AM

-- October 22, 2024 --

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo (vadadustat) for Patients on Dialysis PRNewswire 8:00 AM

-- October 15, 2024 --

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 PRNewswire 8:00 AM

-- October 10, 2024 --

CMS Grants TDAPA Reimbursement for Vafseo (vadadustat) beginning January 1, 2025 PRNewswire 8:00 AM

-- October 7, 2024 --

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo (vadadustat) for Patients on Dialysis PRNewswire 8:00 AM

-- October 1, 2024 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM

-- September 5, 2024 --

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (vadadustat) for Patients on Dialysis PRNewswire 8:00 AM

-- September 3, 2024 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:17 PM